Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K Callahan, Harriet Kluger, Michael A Postow, et al.
Advances in Therapy
|
July 10, 2015
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
Fiona McPhee, Yoshiyuki Suzuki, Joji Toyota, et al.
Frontiers in Oncology
|
February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
Corey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
May 17, 2011
Is coronary computed tomography angiography a resource sparing strategy in the risk stratification and evaluation of acute chest pain? Results of a randomized controlled trial
Adam H Miller, Paul E Pepe, Ron Peshock, et al.
Journal of Pancreatic Cancer
|
September 28, 2019
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
Vaibhav Sahai, M Wasif Saif, Aparna Kalyan, et al.
Hepatology (Baltimore, Md.)
|
January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Journal of the American Academy of Dermatology
|
April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method
Amit G Pandya, Linda S Hynan, Rafia Bhore, et al.
The Journal of Infectious Diseases
|
September 8, 2021
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial
Anita Boyapati, Matthew F Wipperman, Peter J Ehmann, et al.
Mbio
|
October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Frontiers in Oncology
|
March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K Callahan, Harriet Kluger, Michael A Postow, et al.
Advances in Therapy
|
July 10, 2015
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
Fiona McPhee, Yoshiyuki Suzuki, Joji Toyota, et al.
Frontiers in Oncology
|
February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
Corey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
May 17, 2011
Is coronary computed tomography angiography a resource sparing strategy in the risk stratification and evaluation of acute chest pain? Results of a randomized controlled trial
Adam H Miller, Paul E Pepe, Ron Peshock, et al.
Journal of Pancreatic Cancer
|
September 28, 2019
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
Vaibhav Sahai, M Wasif Saif, Aparna Kalyan, et al.
Hepatology (Baltimore, Md.)
|
January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Journal of the American Academy of Dermatology
|
April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method
Amit G Pandya, Linda S Hynan, Rafia Bhore, et al.
The Journal of Infectious Diseases
|
September 8, 2021
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial
Anita Boyapati, Matthew F Wipperman, Peter J Ehmann, et al.
Mbio
|
October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Frontiers in Oncology
|
March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Page
of 6